[
{
	"page":"ENAS5271_1.0.0.0",
	"text":"1.0.0.0 Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth de Vries, Alan Horwich, Solange Peters, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic. ESMO CLINICAL PRACTICE GUIDELINES Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M and Ladetto M, on behalf of the ESMO Guidelines Working Group Ann Oncol 2014;25(Suppl 3):iii70–5 https://​annonc.oxfordjournals.org/​content/​25/​suppl_3/​iii70.​full.​pdf+html Diffuse large B cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-​Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M and Ladetto M, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26(Suppl 5):v116–25 https://​annonc.oxfordjournals.org/​content/​26/​suppl_5/​v116.​full.​pdf+html Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J and Ladetto M, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv62–71 https://​academic.​oup.com/​annonc/​article-pdf/​28/​suppl_4/​iv62/​3958157/​mdx223.pdf Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U and Ladetto M, on behalf of the ESMO Guidelines Committee Ann Oncol 2016;27(Suppl 5):v83–90 https://​annonc.​oxfordjournals.​org/​content/​27/​suppl_5/​v83.full.​pdf+html Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U and Dreyling M, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi155–9 https://​annonc.oxfordjournals.org/​content/​24/​suppl_6/​vi155.​full.​pdf+html Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Zucca E, Copie-​Bergman C, Ricardi U, Thieblemont C, Raderer M and Ladetto M, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi144–8 https://​annonc.oxfordjournals.org/​content/​24/​suppl_6/​vi144.​full.​pdf+html Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Willemze R, Hodak E, Zinzani PL, Specht L and Ladetto M, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi149–54 https://​annonc.oxfordjournals.org/​content/​24/​suppl_6/​vi149.​full.​pdf+html Peripheral T cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up d’Amore F, Gaulard P, Trümper L, Corradini P, Kim W-S, Specht L, Bjerregaard Pedersen M and Ladetto M, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26(Suppl 5):v108–15 https://​annonc.​oxfordjournals.org/​content/​26/​suppl_5/​v108.​full.pdf+html Extranodal diffuse large B cell lymphoma (DLBCL) and primary mediastinal B cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, Campo E and Ladetto M, on behalf of the ESMO Guidelines Committee Ann Oncol 2016;27(Suppl 5):v91–102 https://​annonc.oxfordjournals.org/​content/​27/​suppl_5/​v91.​full.​pdf+html Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M and Buske C, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26(Suppl 5):v78–84 https://​annonc.oxfordjournals.org/​content/​26/​suppl_5/​v78.​full.​pdf+html Chronic lymphocytic leukaemia: eUpdate published online September 2016 Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M and Buske C, on behalf of the ESMO Guidelines Committee Ann Oncol 2016; 27(Suppl 5): v143 https://​academic.​oup.com/​annonc/​article-​pdf/​27/suppl_5/​v143/​1741718/​mdw359.pdf Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv149 https://​academic.​oup.com/​annonc/​article-​pdf/28/​suppl_4/​iv149/​3958163/​mdx242.pdf Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-​up Robak T, Matutes E, Catovsky D, Zinzani PL and Buske C, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26(Suppl 5):v100–7 https://​annonc.oxfordjournals.org/​content/​early/​2015/08/12/​annonc.​mdv200.​full.​pdf+html ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPGs) on the management of lymphomas (Hodgkin’s lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, follicular lymphoma, Waldenström’s macroglobulinaemia, gastric marginal zone lymphoma of MALT type, primary cutaneous lymphomas, peripheral T cell lymphomas, extranodal diffuse large B cell lymphoma and primary mediastinal B cell lymphoma, chronic lymphocytic leukaemia and hairy cell leukaemia). Key content includes diagnostic criteria, staging of disease, treatment plans and follow-​up. The ESMO CPGs on lymphomas are intended to provide you with a set of recommendations for the best standards of care for lymphoma, using evidence-​based medicine. Implementation of ESMO CPGs facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. Please note that this document is not exhaustive and it may be important to refer to the full CPGs for critical clinical decision-​making. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on evidence-​based management of lymphomas. Please visit http://www.esmo.org or http://​oncologypro.esmo.org to view the full guidelines."
},
{
	"page":"ENAS5271_2.0.0.0",
	"text":"2.0.0.0 Diagnosis The diagnosis of diffuse large B-‍cell lymphoma (DLBCL) should be performed in a reference haematopathology laboratory with expertise in morphological interpretation and the facilities to carry out the full range of phenotypic and molecular investigations required A surgical excision biopsy, which allows assessment of nodal architecture and adequate material for phenotypic and molecular analysis, remains the optimal method of diagnosis Unfixed samples, which allow flow cytometry and high-‍quality DNA/‍RNA extraction, are preferred Needle-‍core and endoscopic biopsies should be used only when surgery is impractical or would entail excessive risk A fine-‍needle aspirate should not be the sole basis for a diagnosis Morphological diagnosis should be confirmed by immunophenotypic investigations, either immunohistochemistry (IHC), flow cytometry or a combination of both Panels used should be able to confirm B-‍cell lineage and be sufficiently comprehensive to distinguish between possible variant forms and alternative diagnoses Diagnosis should be made according to the current World Health Organization (WHO) classification"
},
{
	"page":"ENAS5271_3.1.0.0",
	"text":"3.0.0.0 Staging and risk assessment 3.1.0.0 Introduction Physical examination, performance status (PS), assessment of B symptoms, complete blood count, routine blood chemistry (including lactate dehydrogenase [LDH] and uric acid) and screening tests for human immunodeficiency virus (HIV), hepatitis B virus (HBV; hepatitis B surface [HBs] antigen, anti-‍HBs and anti-‍hepatitis B core [HBc] antibodies) and hepatitis C virus (HCV) are required Protein electrophoresis is recommended Fluorodeoxyglucose (FDG) positron emission tomography (PET)/‍computed tomography (CT) is the gold standard for staging DLBCL When contrast-‍enhanced CT is not routinely performed prior to PET-‍CT, a full diagnostic high-‍dose contrast-enhanced CT should be carried out when necessary, in combination with PET-‍CT and after the PET scan Baseline contrast-enhanced CT can determine if the low-‍dose, non-‍enhanced CT part of the PET-‍CT scan will be sufficient for restaging Biopsy is not required when bone or marrow involvement indicating advanced stage disease is demonstrated by PET-‍CT, but it is appropriate when PET is negative and biopsy results would change prognosis and treatment, particularly when a reduced number of immunochemotherapy cycles is proposed Magnetic resonance imaging (MRI) is the modality of choice when central nervous system (CNS) lymphoma is suspected A diagnostic lumbar puncture should be considered for high-‍risk patients and flow cytometry enhances the detection of lymphoma cells Cardiac function, with left ventricular ejection fraction (LVEF), should be assessed before treatment Staging should be conducted according to the Ann Arbor classification system, as shown in the table here"
},
{
	"page":"ENAS5271_3.2.0.0",
	"text":"3.2.0.0 Ann Arbor staging classification STAGE I Involvement of a single lymphatic region (I) or localised involvement of single extralymphatic organ or site (IE) II Involvement of two or more lymphatic regions on the same side of the diaphragm (II) or localised involvement of a single extralymphatic organ or site and of one or more lymphatic regions on the same side of the diaphragm (IIE) III Involvement of lymphatic regions on both sides of the diaphragm IV Diffuse or disseminated involvement of one or more extralymphatic organs with or without lymphatic involvement The International Prognostic Index (IPI) and age-‍adjusted IPI (aaIPI) should be used to calculate prognosis, as shown here Other factors potentially affecting prognosis and treatment, such as the maximum disease bulk, should also be assessed"
},
{
	"page":"ENAS5271_4.1.0.0",
	"text":"4.0.0.0 Treatment 4.1.0.0 Overview Treatment strategies should be stratified according to age, IPI and feasibility of dose-‍intensified approaches, as shown here"
},
{
	"page":"ENAS5271_4.2.1.0",
	"text":"4.2.0.0 Recommended treatment strategies 4.2.1.0 AAIPI in patients ≤60 years AAIPI IN PATIENTS ≤ 60 YEARS Risk factors Serum LDH > normal     Stage III–IV     Performance status 2–4   Risk categories Low 0 98 (96–100) Low-‍intermediate 1 92 (87–95) High-‍intermediate 2 75 (66–82) High 3 CI, confidence interval; aaIPI, age-adjusted International Prognostic Index; LDH, lactate dehydrogenase"
},
{
	"page":"ENAS5271_4.2.2.0",
	"text":"4.2.2.0 Patients ≤60 years PATIENTS ≤ 60 YEARS IPI low-‍risk (aaIPI = 0) and no bulk IPI low-‍risk (aaIPI = 0) with bulk or IPI low-‍intermediate-‍risk (aaIPI = 1) IPI high-‍intermediate-‍risk or IPI high-‍risk (aaIPI ≥ 2) R-‍CHOP21 x 6 R-‍ACVBP and sequential consolidation OR R-‍CHOP21 x 6 IFRT on bulk R-‍CHOP21 x 6–8 OR R-‍CHOP14 x 6 with 8 R Consider more intensive regimens in selected patients: R-‍CHOEP14 x 6 OR R-‍CHOP or R-‍ACVBP plus HDCT with ASCT Consider CNS prophylaxis in patients at risk for CNS progression"
},
{
	"page":"ENAS5271_4.2.3.0",
	"text":"4.2.3.0 Elderly (>60 years) ELDERLY (> 60 YEARS) Fit, 60–80 years > 80 years without cardiac dysfunction Unfit or frail or > 60 years with cardiac dysfunction R-‍CHOP21 x 6–8 (R-‍CHOP21 x 6 for IPI low-‍risk) OR R-‍CHOP14 x 6 with 8 R Attenuated regimens: R-‍miniCHOP21 x 6 Doxorubicin substitution with gemcitabine, etoposide, liposomal doxorubicin or others: R-C(X)OP21 x 6 OR Palliative care Consider CNS prophylaxis in patients at risk"
},
{
	"page":"ENAS5271_4.2.4.0",
	"text":"4.2.4.0 First relapse/‍ progression FIRST RELAPSE/‍PROGRESSION Eligible for transplant Not eligible for transplant Platinum-‍based chemotherapy regimens (i.e. R-‍DHAP, R-ICE, R-GDP) as salvage treatment Platinum-‍ and/‍or gemcitabine-‍based regimens For chemosensitive patients: R-‍HDCT with ASCT as remission consolidation Clinical trials with novel drugs Consider alloSCT in patients relapsed after R-‍HDCT with ASCT or in patients with poor risk factors at relapse"
},
{
	"page":"ENAS5271_4.2.5.0",
	"text":"4.2.5.0 >2 relapses/ progressions > 2 RELAPSES/‍PROGRESSIONS Eligible for transplant Not eligible for transplant AlloSCT Clinical trials with novel drugs Clinical trials with novel drugs Palliative care aaIPI, age-adjusted IPI; ACVBP, doxorubicin/vindesine/cyclophosphamide/bleomycin/prednisolone; alloSCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantation; CHOEP, cyclophosphamide/doxorubicin/vincristine/etoposide/prednisolone; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; CNS, central nervous system; DHAP, cisplatin/high-dose cytarabine/dexamethasone; GDP, cisplatin/gemcitabine/dexamethasone; HDCT, high-dose chemotherapy; ICE, ifosfamide/carboplatin/etoposide; IFRT, involved-field radiotherapy; IPI, International Prognostic Index; R, rituximab; R-C(X)OP, R-CHOP with substitution of doxorubicin with another agent; R-miniCHOP21, attenuated immunochemotherapy regimen every 21 days"
},
{
	"page":"ENAS5271_4.3.0.0",
	"text":"4.3.0.0 Treatment stratified according to age Inclusion in a clinical trial is recommended whenever possible When tumour load is high, precautions, such as several days’ prephase administration of oral prednisone to avoid tumour lysis syndrome, are advised Dose reductions due to haematological toxicity should be avoided Febrile neutropaenia justifies prophylactic use of haematopoietic growth factors in patients treated with curative intent and those > 60 years of age Young low-risk patients (aaIPI = 0) without bulky disease The current standard is 6 cycles of cyclophosphamide/doxorubicin/vincristine/‍prednisone (CHOP) combined with six doses of rituximab, every 21 days (R-‍CHOP21) Consolidation by radiotherapy (RT) to initial non-‍bulky sites has no proven benefit, with or without rituximab Young low-intermediate-risk patients (aaIPI = 1) or IPI low-risk (aaIPI = 0) patients with bulky disease R-‍CHOP21 × 6 with RT to sites of previous bulky disease is effective The intensified regimen of rituximab-‍doxorubicin/vindesine/cyclophosphamide/bleomycin/‍prednisolone (R-‍ACVBP) given every 2 weeks followed by sequential consolidation, is an effective alternative, and has been shown to improve survival compared with 8 cycles of rituximab-‍cyclophosphamide/doxorubicin/vincristine/ prednisolone (R-‍CHOP), although RT was omitted in both arms Young high-risk and high-intermediate-risk patients (aaIPI ≥ 2) There is no current standard for these patients and enrolment in clinical trials is a priority 6–8 cycles of CHOP combined with eight doses of rituximab given every 21 days are commonly used Intensive treatments can be considered in selected patients Dose-‍dense R-‍CHOP, given every 14 days (R-‍CHOP14), has no survival benefit over standard R-‍CHOP21 Direct comparisons with R-‍CHOP of the frequently used intensive R-‍ACVBP or rituximab-‍cyclophosphamide/doxorubicin/vincristine/etoposide/prednisolone (R-‍CHOEP) regimens have not been performed The use of high-‍dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) following rituximab-‍chemotherapy has not shown consistent improvements in outcome compared with rituximab-‍chemotherapy alone and remains experimental This approach may be used for selected high-‍risk patients The role of RT consolidation to initial sites of bulky disease is unknown The use of interim PET to select patients who may benefit from consolidative ASCT or from RT is under evaluation Patients aged 60–80 years The current standard is 6–8 cycles of CHOP plus eight doses of rituximab given every 21 days R-‍CHOP14 has not shown a survival advantage over R-‍CHOP21 If used, 6 cycles of CHOP with 8 cycles of rituximab are sufficient In localised disease, consolidation RT showed no benefit prior to the introduction of rituximab, but it may improve outcome in patients with bulky disease Extended rituximab treatment has been shown to improve outcome in poor prognosis patients without increasing toxicity A comprehensive geriatric assessment, to ascertain comorbidities and functional decline, is recommended to guide treatment choices in these patients R-‍CHOP can generally be used up to the age of 80 years in fit patients but modulation of treatment according to geriatric assessment is recommended Patients aged > 80 years Rituximab with attenuated chemotherapy (R-‍miniCHOP) can induce complete remission and prolong survival in fit patients Substitution of doxorubicin with gemcitabine, etoposide or liposomal doxorubicin, or even its omission, can be considered from the outset or after a few cycles in patients with cardiac dysfunction or who are frail or unfit"
},
{
	"page":"ENAS5271_4.4.0.0",
	"text":"4.4.0.0 CNS prophylaxis CNS prophylaxis is recommended for patients with high-‍intermediate-‍risk and high-‍risk IPI, particularly those with more than one extranodal site or elevated LDH, or patients with testicular, renal or adrenal involvement MYC rearrangement is also associated with a high risk of CNS relapse Intrathecal methotrexate administration may not be an optimal method but intravenous (IV) high-‍dose methotrexate is related to efficient disease control and is under clinical investigation"
},
{
	"page":"ENAS5271_4.5.0.0",
	"text":"4.5.0.0 Special considerations for some DLBCLs Patients with HIV infection should receive the same treatment as HIV-‍negative patients, but with antiviral therapy Patients previously exposed to HBV (HBs antigen-‍negative, anti-‍HBc-‍positive) are at risk of reactivation during R-‍CHOP treatment; antiviral prophylaxis or periodic HBV DNA monitoring, with antiviral treatment if reactivation occurs, are recommended"
},
{
	"page":"ENAS5271_4.6.1.0",
	"text":"4.6.0.0 Response evaluation 4.6.1.0 Post-‍treatment evaluation FDG-‍PET-‍CT is the recommended standard for post-‍treatment assessment The Lugano classification based on the visual Deauville criteria (five-‍point scale) has proposed different, ‘metabolic response’ categories, as shown below PET FIVE-‍POINT SCALE (DEAUVILLE CRITERIA) 1 No uptake 2 Uptake ≤ mediastinum 3 Uptake > mediastinum but ≤ liver 4 Moderately increased uptake compared to liver 5 Markedly increased uptake to liver and/‍or new lesions PET, positron emission tomography Complete metabolic response is indicated by Deauville scores 1–3, with scores 4 and 5 indicating residual disease A biopsy is recommended when there is residual metabolically active tissue and salvage treatment is being considered"
},
{
	"page":"ENAS5271_4.6.2.0",
	"text":"4.6.2.0 Interim evaluation Imaging with CT or PET-‍CT after 3–4 cycles can be used to rule out progression Changing treatment solely on PET-‍CT is discouraged unless there is clear evidence of progression Early PET imaging, after 1–2 cycles, may be predictive of outcome but is currently limited to the clinical trial setting"
},
{
	"page":"ENAS5271_5.1.0.0",
	"text":"5.0.0.0 Follow-‍up 5.1.0.0 General follow up A history and physical examination should be conducted every 3 months for 1 year, every 6 months for an additional 2 years and then annually, with a focus on the development of secondary tumours or other long-‍term side effects of chemotherapy Blood counts should be performed at 3, 6, 12 and 24 months and then only as needed for evaluation of suspicious symptoms or clinical findings in patients suitable for further therapy CT scanning at 6, 12 and 24 months after treatment is common but routine imaging of patients in complete remission does not provide any outcome benefits and may increase the incidence of secondary malignancies Routine PET scan surveillance is not recommended High-‍risk patients with curative options may require more frequent evaluation"
},
{
	"page":"ENAS5271_5.2.1.0",
	"text":"5.2.0.0 Relapsed and refractory DLBCL 5.2.1.0 Diagnosis, staging and risk assessment Suspected relapse on imaging should be confirmed by a needle-‍core biopsy before proceeding to second-‍line treatment Patients amenable to curative therapy should undergo the same staging and risk assessments performed at first diagnosis"
},
{
	"page":"ENAS5271_5.2.2.0",
	"text":"Treatment, response evaluation and follow-up 5.2.2.0 Treatment, response evaluation and FU Recommendations are based on the assumption that patients received adequate rituximab and anthracycline first-‍line therapy In patients < 65–70 years of age with good PS and no major organ dysfunction, salvage regimens with rituximab and chemotherapy followed, in responsive patients, by HDCT and ASCT, are recommended Rituximab-‍cisplatin/high-dose cytarabine/dexamethasone (R-‍DHAP) and rituximab-‍ifosfamide/carboplatin/etoposide (R-ICE) give similar outcomes Rituximab-cisplatin/gemcitabine/dexamethasone (R-GDP) has similar efficacy but less toxicity than R-‍DHAP The potential benefits of R-‍DHAP in germinal centre B-‍cell sub-‍types require confirmation Carmustine/etoposide/cytarabine/melphalan (BEAM) is the most commonly used high-‍dose regimen Involved-‍field RT (IFRT) or iceberg RT may be useful in limited-‍stage disease but have not been evaluated in controlled trials Rituximab maintenance therapy is not recommended Allogeneic stem cell transplantation (alloSCT) may be considered in patients with refractory disease, early relapse or relapse after ASCT When high-‍dose therapy is not suitable, salvage regimens, including rituximab-‍gemcitabine/oxaliplatin (R-‍GEMOX), can be used Pixantrone, a new anthracycline-‍like drug with reduced cardiotoxicity, has shown efficacy in heavily treated patients Patients should preferably be enrolled in clinical trials investigating novel agents First-‍line treatment response evaluation criteria should be used after 3–4 cycles of salvage therapy and after the end of all therapy Follow-‍up is the same as for first response"
},
{
	"page":"ENAS5271_6.0.0.0",
	"text":"6.0.0.0 Personalised medicine Currently, no molecularly targeted agents are appropriate for routine use in clinical practice Agents under investigation in activated B-‍cell DLBCL include bortezomib and lenalidomide, which target the NF-KB pathway, and the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib"
},
{
	"page":"ENAS5271_7.1.0.0",
	"text":"7.0.0.0 Summary of recommendations 7.1.0.0 Diagnosis The diagnosis of DLBCL should be performed in a reference haematopathology laboratory with expertise in morphological interpretation and the facilities to carry out the full range of phenotypic and molecular investigations required A surgical excision biopsy remains the optimal method of diagnosis Needle-‍core and endoscopic biopsies should be used only when surgery is impractical or would entail excessive risk A fine-‍needle aspirate should not be the sole basis for a diagnosis Morphological diagnosis should be confirmed by immunophenotypic investigations, either IHC, flow cytometry or a combination of both Diagnosis should be made according to the current WHO classification"
},
{
	"page":"ENAS5271_7.2.0.0",
	"text":"7.2.0.0 Staging and risk assessment Physical examination, PS, assessment of B symptoms, complete blood count, routine blood chemistry (including LDH and uric acid) and screening tests for HIV, HBV and HCV are required Protein electrophoresis is recommended FDG-‍PET-‍CT imaging is the gold standard for staging DLBCL When contrast-enhanced CT is not routinely performed prior to PET-‍CT, a full diagnostic high-‍dose contrast-enhanced CT should be carried out when necessary, in combination with PET-‍CT Biopsy is not required when bone or marrow involvement indicating advanced-‍stage disease is demonstrated by PET-‍CT, but it is appropriate when PET is negative and biopsy results would change prognosis and treatment, particularly when a reduced number of immunochemotherapy cycles is proposed MRI is the modality of choice when CNS lymphoma is suspected A diagnostic lumbar puncture should be considered for high-‍risk patients Cardiac function, with LVEF, should be assessed before treatment Staging should be conducted according to the Ann Arbor classification system The IPI and aaIPI should be used to calculate prognosis"
},
{
	"page":"ENAS5271_7.3.1.0",
	"text":"7.3.0.0 Treatment 7.3.1.0 Treatment stratified according to age Treatment should be stratified according to age, IPI and feasibility of dose-intensified approaches Inclusion in a clinical trial is recommended whenever possible When tumour load is high, precautions to avoid tumour lysis syndrome are advised Dose reductions due to haematological toxicity should be avoided Febrile neutropaenia justifies prophylactic use of haematopoietic growth factors in patients treated with curative intent and those > 60 years of age Young low-‍risk patients (aaIPI = 0) without bulky disease R-‍CHOP21 × 6 is the current standard RT consolidation to initial non-‍bulky sites has no proven benefit, with or without rituximab Young low-‍intermediate-‍risk patients (aaIPI = 1) or IPI low-‍risk (aaIPI = 0) patients with bulky disease R-‍CHOP21 × 6, with RT to sites of previous bulky disease, or R-‍ACVBP given every 2 weeks can be recommended Young high-‍risk and high-‍intermediate-‍risk patients (aaIPI ≥ 2) There is no current standard of treatment and enrolment in clinical trials is a priority 6–8 cycles of CHOP combined with eight doses of rituximab given every 21 days are commonly used Intensive R-‍CHOP14, R-‍ACVBP or R-‍CHOEP can be considered in selected patients HDCT with ASCT following rituximab-‍chemotherapy remains experimental or can be used for selected high-‍risk patients The role of RT consolidation to initial sites of bulky disease is unknown Patients aged 60–80 years The current standard is 6–8 cycles of CHOP plus eight doses of rituximab given every 21 days R-‍CHOP14 has no survival advantage over R-‍CHOP21, but if used, 6 cycles of CHOP with 8 cycles of rituximab are sufficient Consolidation RT may improve outcome in patients with bulky disease A comprehensive geriatric assessment, to ascertain comorbidities and functional decline, is recommended to guide treatment choices in elderly, poor-‍prognosis patients R-‍CHOP can generally be used up to the age of 80 years in fit patients but modulation of treatment according to geriatric assessment is recommended Patients aged > 80 years R-‍miniCHOP can induce complete remission and prolonged survival in fit patients Substitution of doxorubicin with gemcitabine, etoposide or liposomal doxorubicin, or even its omission, can be considered from the outset or after a few cycles in patients with cardiac dysfunction or who are frail or unfit"
},
{
	"page":"ENAS5271_7.3.2.0",
	"text":"7.3.2.0 CNS prophylaxis CNS prophylaxis is recommended for patients with high-‍intermediate-‍risk and high-‍risk IPI disease, particularly those with more than one extranodal site or elevated LDH, or patients with testicular, renal or adrenal involvement High-‍dose IV methotrexate is related to efficient disease control"
},
{
	"page":"ENAS5271_7.3.3.0",
	"text":"7.3.3.0 Special considerations for some DLBCLs Patients with HIV infection should receive the same treatment as HIV-‍negative patients, but with antiviral therapy Antiviral prophylaxis or periodic HBV DNA monitoring, with antiviral treatment as necessary, are recommended for patients at risk of HBV reactivation during R-‍CHOP treatment"
},
{
	"page":"ENAS5271_7.3.4.0",
	"text":"7.3.4.0 Response evaluation Post-‍treatment evaluation FDG-‍PET-‍CT is the recommended standard for post-‍treatment assessment A biopsy is recommended when there is residual metabolically active tissue and salvage treatment is being considered Interim evaluation Imaging with CT or PET-‍CT after 3–4 cycles can be used to rule out progression Changing treatment solely on PET-‍CT is discouraged, unless there is clear evidence of progression"
},
{
	"page":"ENAS5271_7.4.1.0",
	"text":"7.4.0.0 Follow-‍up 7.4.1.0 General follow up A history and physical examination should be conducted every 3 months for 1 year, every 6 months for an additional 2 years and then annually, with a focus on the development of secondary tumours or other long-‍term side effects of chemotherapy Blood counts should be performed at 3, 6, 12 and 24 months and then only as needed for evaluation of suspicious symptoms or clinical findings in patients suitable for further therapy CT scanning at 6, 12 and 24 months after the end of treatment is common practice, but routine imaging of patients in complete remission does not provide outcome benefits and may increase the incidence of secondary malignancies Routine PET scan surveillance is not recommended High-‍risk patients with curative options may require more frequent evaluation"
},
{
	"page":"ENAS5271_7.4.2.1",
	"text":"7.4.2.0 Relapsed and refractory DLBCL 7.4.2.1 Diagnosis, staging and risk assessment Suspected relapse on imaging should be confirmed by a needle-‍core biopsy before proceeding to second-‍line treatment Patients amenable to curative therapy should undergo the same staging and risk assessments performed at first diagnosis"
},
{
	"page":"ENAS5271_7.4.2.2",
	"text":"Treatment, response evaluation and follow-up 7.4.2.2 Treatment, response evaluation and follow-‍up In patients < 65–70 years of age with good PS and no major organ dysfunction, salvage rituximab-‍chemotherapy regimens followed, in responsive patients, by HDCT and ASCT, are recommended R-‍DHAP, R-ICE and R-GDP give similar outcomes BEAM is the most commonly used high-‍dose regimen IFRT may be useful in limited-‍stage disease Rituximab maintenance therapy is not recommended AlloSCT may be considered in patients with refractory disease, early relapse or relapse after ASCT Salvage regimens, including R-‍GEMOX, can be used when HDCT/‍ASCT is not feasible Patients should preferably be enrolled in clinical trials investigating novel agents First-‍line treatment response evaluation criteria should be used after 3–4 cycles of salvage therapy and after the end of all therapy Follow-‍up is the same as for first response"
},
{
	"page":"ENAS5271_7.5.0.0",
	"text":"7.5.0.0 Personalised medicine Currently, no molecularly targeted agents are appropriate for routine use in clinical practice"
},
{
	"page":"ENAS5271_8.0.0.0",
	"text":"aaIPI age-‍adjusted International Prognostic Index ABC activated B cell ABVD doxorubicin/‍bleomycin/‍vinblastine/‍dacarbazine ACVBP doxorubicin/‍vindesine/‍cyclophosphamide/‍bleomycin/‍prednisolone AITL angioimmunoblastic T cell lymphoma ALCL anaplastic large cell lymphoma ALK anaplastic lymphoma kinase alloHSCT allogeneic haematopoietic stem cell transplantation alloSCT allogeneic stem cell transplantation anti-‍HBc hepatitis B core antibody anti-‍HBs hepatitis B surface antibody AP alkaline phosphatase AraC cytarabine ASCT autologous stem cell transplantation AspaMetDex L-‍asparaginase/​methotrexate/​dexamethasone autoHSCT autologous hematopoietic stem cell transplantation BAC bendamustine/​cytarabine BCL2 B cell lymphoma 2 BCR B cell receptor BEACOPPesc escalated dose of bleomycin/​etoposide/​doxorubicin/​cyclophosphamide/​vincristine/​procarbazine/​prednisone BEAM carmustine/​etoposide/​cytarabine/​melphalan BM bone marrow BR bendamustine/‍rituximab Btk Bryton&#39;s tyrosine kinase BV brentuximab vedotin C-‍ALCL cutaneous anaplastic large cell lymphoma CBCL cutaneous B cell lymphoma CCNU lomustine CDK cyclin-dependent kinase cHL classical Hodgkin’s lymphoma CHOEP cyclophosphamide/‍​doxorubicin/​vincristine/​etoposide/​prednisolone CHOP cyclophosphamide/​doxorubicin/​vinccristine/​prednisone CHVP cyclophosphamide/​​doxorubicin/​​etoposide/​​prednisone CI confidence interval Clb chlorambucil CLL chronic lymphocytic leukaemia CMR complete metabolic response CMV cytomegalovirus CNS central nervous system CPGs Clinical Practice Guidelines CR complete remission/response CR1 first complete remission CRP C-‍reactive protein CS clinical stage CSF cerebrospinal fluid CT computed tomography CTCL cutaneous T cell lymphoma CVP cyclophosphamide/​vincristine/​​prednisone DA-‍EPOCH-‍R dose-‍adjusted etoposide/​​prednisone/​​vincristine/​​cyclophosphamide/​doxorubicin-‍rituximab DAT direct antiglobulin test DCR dexamethasone/​cyclophosphamide/‍rituximab DHAP dexamethasone/​high-‍dose cytarabine/​cisplatin DLBCL diffuse large B cell lymphoma DOR duration of response EATL enteropathy-‍associated T cell lymphoma EBV Epstein-‍Barr virus ECOG Eastern Cooperative Oncology Group ECP extracorporeal photophoresis EFS event-free survival EGD oesophagogastroduodenoscopy EMA epithelial membrane antigen ENKTCL extranodal natural killer/T cell lymphoma EORTC European Organisation for Research and Treatment of Cancer EPOCH etoposide/​vincristine/​doxorubicin/‍​cyclophosphamide/​prednisone ESMO European Society for Medical Oncology ESR erythrocyte sedimentation rate FACS fluorescence-activated cell sorting FC fludarabine/​cyclophosphamide FCR fludarabine/​cyclophosphamide/​rituximab FDC follicular dendritic cell FDG fluorodeoxyglucose FDG-‍PET fluorodeoxyglucose positron emission tomography FISH fluorescence in situ hybridisation FL follicular lymphoma FLIPI Follicular Lymphoma-‍specific International Prognostic Index FM fludarabine/​mitoxantrone FND cyclophosphamide/​​vincristine/​​prednisolone FTH follicular T-helpe GC germinal centre GDP cisplatin/‍​gemcitabine/​dexamethasone GELA Groupe d’Etude des Lymphomes de l’Adulte GHSG German Hodgkin Study Group GI gastrointestinal Hb haemaglobin HBc hepatitis B core HBs hepatitis B surface HBsAG hepatitis B surface antigen HBV hepatitis B virus HCL hairy cell leukaemia HCL-V hairy cell leukaemia variant HCV hepatitis C virus HD Hodgkin’s disease HD-AraC high-‍dose cytarabine HD-‍MTX high-‍dose methotrexate HDCT high-‍dose chemotherapy HDCT/‍ASCT high-‍dose chemotherapy followed by autologous stem cell transplantation HIV human immunodeficiency virus HL Hodgkin’s lymphoma HLA human leucocyte antigen HPS haemophagocytic syndrome HRS Hodgkin and Reed-‍Sternberg HSCT haematopoietic stem cell transplantation HSTCL hepatosplenic T cell lymphoma HTLV-1 human T lymphotropic virus-1 Hyper-CVAD cyclophosphamide/‍​vincristine/​doxorubicin/​dexamethasone ICE ifosfamide/‍​carboplatin/‍​etoposide IELSG International Extranodal Lymphoma Study Group IFNα interferon alpha IFRT involved-‍field radiotherapy Ig immunoglobulin IGEV ifosfamide/‍​gemcitabine/‍​vinorelbine IGHV immunoglobulin heavy chain variable IHC immunohistochemistry IL intralesional ILROG International Lymphoma Radiation Oncology Group IPI International Prognostic Index ISCL International Society for Cutaneous Lymphomas ISRT involved-‍site radiotherapy ISSWM International Prognostic Scoring System for Waldenström’s macroglobulinaemia IT intrathecal IV intravenous IVAC ifosfamide/​cytarabine/​etoposide IVE ifosfamide/​vincristine/​etoposide KPS Karnofsky performance score LDH lactate dehydrogenase LP lymphocyte predominant LPDs lymphoproliferative disorders LVEF left ventricular ejection fraction LyP lymphomatoid papulosis LYSA Lymphoma Study Assocation M metastasis MALT mucosa-‍associated lymphoid tissue maxi-CHOP maximum-strength CHOP MC mantle cell MCL mantle cell lymphoma MCP melphalan/​chlorambucil/​prednisone MF mycosis fungoides MIPI Mantle Cell Lymphoma International Prognostic Index MIPI-c combined mantle cell lymphoma International Prognostic Index MRD minimal residual disease MRI magnetic resonance imaging mTOR mechanistic target of rapamycin MTX methotrexate N node n/a not applicable NC no change neg negative NHL non-‍Hodgkin’s lymphoma NK natural killer NKTCL natural killer/​T cell lymphoma NLPHL nodular lymphocyte-‍predominant Hodgkin’s lymphoma NR not reached OFAR oxaliplatin/​fludarabine/​cytarabine/​rituximab ORR overall response rate OS overall survival PB peripheral blood PBL primary diffuse large B cell lymphoma of the breast PBoL primary diffuse large B cell lymphoma of the bone PCFCL primary cutaneous follicle centre lymphoma PCL primary cutaneous lymphomas PCLBCL-‍LT primary cutaneous diffuse large B cell lymphoma, leg type PCMZL primary cutaneous marginal zone lymphoma PCNSL primary central nervous system lymphoma PCR polymerase chain reaction PDL programmed cell death ligand PEP-C prednisone/​etoposide/​procarbazine/​cyclophosphamide PET positron emission tomography PET CT positron emission tomography-‍computed tomography PFS progression-‍free survival PI3K phosphoinositide 3-‍kinase PMBCL primary mediastinal large B cell lymphoma pMRD probable minimal residual disease PPI proton pump inhibitor PR partial response PS performance status PTCL peripheral T cell lymphoma PTCL-‍NOS peripheral T cell lymphoma – not otherwise specified PTL primary testicular lymphoma PUVA psoralens and ultraviolet A R rituximab R-‍ACVBP rituximab-‍doxorubicin/​vindesine/​cyclophosphamide/​bleomycin/​prednisolone R-BAC rituximab-bendamustine/​cytarabine R-‍CHOEP rituximab-‍cyclophosphamide/​doxorubicin/​vincristine/​prednisone/​etoposide R-‍CHOEP14 rituximab-‍cyclophosphamide/​doxorubicin/​vincristine/​prednisone/​etoposide, every 14 days R-‍CHOP rituximab-‍cyclophosphamide/​doxorubicin/​vincristine/​prednisolone R-‍CHOP14 rituximab-‍cyclophosphamide/​doxorubicin/​vincristine/​prednisone, every 14 days R-‍CHOP21 rituximab-‍cyclophosphamide/​doxorubicin/​vincristine/​prednisone, every 21 days R-‍CHVP-‍IFN rituximab-‍cyclophosphamide/​doxorubicin/​etoposide/​prednisone-‍interferon R-CVP rituximab-‍cyclophosphamide/​vincristine/​prednisolone R-‍DHAP rituximab/‍​dexamethasone/‍​high-dose cytarabine/‍​cisplatin R-FC rituximab-fludarabine/‍​cyclophosphamide R-FM rituximab-fludarabine/​mitoxantrone R-FND rituximab-‍cyclophosphamide/​vincristine/​prednisolone R-GDP rituximab-cisplatin/​gemcitabine/​dexamethasone R-‍GEMOX rituximab-‍gemcitabine/​oxaliplatin R-‍HDCT rituximab plus high-‍dose chemotherapy R-‍Hyper-‍CVAD rituximab plus fractionated cyclophosphamide/​vincristine/​anthracycline/​dexamethasone R-ICE rituximab-ifosfamide/‍​carboplatin/‍​etoposide R-‍MACOP-‍B rituximab-methotrexate/​doxorubicin/​cyclophosphamide/​vincristine/​prednisolone-bleomycin R-MCP rituximab-mitoxantrone/​chlorambucil/​prednisone R-‍miniCHOP rituximab with attenuated chemotherapy R-‍VACOP-‍B rituximab-‍etoposide/​doxorubicin/​cyclophosphamide/​vincristine/​prednisolone-‍bleomycin RIC-‍alloSCT reduced-‍intensity conditioning allogeneic stem cell transplantation RIT radioimmunotherapy rRD responding residual disease RR response rate RT radiotherapy SC subcutaneous SLL small lymphocytic leukaemia SMILE dexamethasone/​methotrexate/​ifosphamide/​L-asparaginase/​etoposide SPTCL subcutaneous panniculitis-‍like T cell lymphoma SS Sézary syndrome T tumour TBI total body irradiation TCR T cell receptor TNMB tumour node metastasis blood TRM transplant-related mortality TSH thyroid-stimulating hormone TTF time to treatment failure TTP time to progression ULN upper limit of normal UVB ultraviolet B VADC vincristine/‍​doxorubicin/​oral dexamethasone/​chlorambucil VR-CAP bortezomib/​cyclophosphamide/​doxorubicin/​prednisone/​rituximab WBC white blood cell WBRT whole brain radiotherapy WHO World Health Organization WM Waldenström’s macroglobulinaemia"
}
]